Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:20 p.m. Eastern Time.
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplant. This first-in-class conditioning antibody is designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. For more information, please visit us at jaspertherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006090/en/
Contacts
Lily Eng
W2O
206-661-8627
leng@w2ogroup.com
Jeet Mahal
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com
Source: Jasper Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20210111006090/en
